The effect of adalimumab injection combined with Fengshi Gutong capsule in the treatment of ankylosing spondylitis with kidney deficiency and governor cold

Shen Yue; Zong Hexiang; Wang Jianxiong; Chu Yiran; Zhao Xu; Ma Lingli; Xu Shengqian

doi:10.3760/j.issn.1673-4777.2024.07.023

Abstract：Objective To observe the clinical effect of adalimumab injection combined with Fengshi Gutong capsule in the treatment of ankylosing spondylitis(AS)of kidney deficiency and governor cold.Methods A total of 77 AS patients diagnosed in the Department of Rheumatology and Immunology,the First Affiliated Hospital of Anhui Medical University from May 2021 to April 2023 were selected.All patients were randomly divided into control group(39 cases)and observation group(38 cases).The control group was treated with adalimumab combined with imrecoxib,and the observation group was treated with adalimumab combined with Fengshi Gutong capsule.The data before treatment,laboratory examination results,disease activity index,clinical compliance rate before and after treatment and safety indicators were compared between the two groups.Results There were no statistically significant differences in all indicators between the two groups before treatment(all P＞0.05).After 6 months of treatment,the physician global assessment(PGA)score,BathAS disease activity index(BASDAI),AS disease activity score(ASDAScrp),erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)in the control group were lower than those before treatment,BASDAI,ESR and CRP in the observation group were lower than those before treatment,and the clinical compliance rate was higher than that before treatment(all P＜0.05).After 12 months of treatment,the finger-ground distance,PGA score,BASDAI,ASDAScrp,ESR and CRP in the control group were lower than those before treatment,and the chest expansion and clinical compliance rate were higher than those before treatment,the finger-ground distance,PGA score,BASDAI,ASDAScrp,ESR and CRP in the observation group were lower than those before treatment,and the lumbar activity and clinical standard rate were higher than those before treatment,and the differences were statistically significant(all P＜0.05).After 12 months of treatment,the incidence of gastrointestinal discomfort in the observation group was lower than that in the control group[0(0/22)vs 16.7％(4/24),x2=4.016,P=0.045].Conclusion Adalimumab injection combined with Fengshi Gutong capsule in the treatment of AS patients with kidney deficiency and governor cold has the same effect as adalimumab injection combined with imrecoxib,which can provide a new choice for the treatment of AS.